Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I will analyze ZETA stock and discuss the risks and upside potential of ZETA

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
24 Oct 2025, 22:21 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I will analyze ZETA stock and discuss the risks and upside potential of ZETA
Source overview

AI-generated source summary

This video analyzes Zeta Global Holdings Corp (ZETA), focusing on its potential as an AI stock. The speaker notes the company has a consistent growth with 28% CAGR since 2021, with revenue growth accelerating and a large base of 245 million individuals. The company is shifting EPS from negative to positive.The speaker claims based on the financial information and the long term customer base of ZETA stock, that ZETA sales multiple of about 3x, should be between 5x to 7x revenues resulting in a 99% upside if the markets adjust it sales level to the financial strength of the company. The target price is inferred as a doubled current price to 37.38 to reflect such growth, the failure bound set around 15 to invalidate the analysis.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail